An Open-label, Non-randomised, Multicentre Study to Allow Continued Access to and Assess the Safety and Tolerability of AZD1775 for Patients Enrolled in AZD1775 Clinical Pharmacology Studies
Latest Information Update: 06 Apr 2022
At a glance
- Drugs Adavosertib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors AstraZeneca
- 21 Jun 2019 Status changed from active, no longer recruiting to completed.
- 21 Mar 2019 Planned End Date changed from 11 Aug 2020 to 5 Mar 2020.
- 21 Mar 2019 Planned primary completion date changed from 11 Aug 2020 to 5 Mar 2020.